Black Diamond Therapeutics to Join Jefferies Global Healthcare Conference

Black Diamond Therapeutics, Inc., a clinical-stage oncology company listed on Nasdaq under the ticker BDTX, has announced that its CEO, Mark Velleca, M.D., Ph.D., will be speaking at the Jefferies Global Healthcare Conference. This event is scheduled to be held from June 4 to June 6, 2024, in New York. Dr. Velleca's fireside chat is set for 7:30 to 7:55 am ET on Wednesday, June 5. Those interested can access a live webcast through the investor relations section of Black Diamond Therapeutics' website. Additionally, a replay of the webcast will be available for 90 days post-event.

Black Diamond Therapeutics specializes in developing MasterKey therapies aimed at targeting families of oncogenic mutations in cancer patients. These innovative treatments are designed to address a wide range of genetically defined tumors, tackle resistance mechanisms, reduce toxicities associated with wild-type cells, and penetrate the brain to treat central nervous system diseases.

The company's pipeline includes two advanced clinical-stage programs. The first is BDTX-1535, a fourth-generation EGFR MasterKey inhibitor capable of penetrating the brain, developed to target EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). The second program is BDTX-4933, a brain-penetrant RAF MasterKey inhibitor designed to target KRAS, NRAS, and BRAF alterations in solid tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!